Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00295165
Registration number
NCT00295165
Ethics application status
Date submitted
21/02/2006
Date registered
23/02/2006
Date last updated
4/12/2013
Titles & IDs
Public title
Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease
Query!
Scientific title
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Induction Study to Assess the Efficacy and Safety of 6µg Sargramostim (Leukine) Administered Subcutaneously Once Daily for 8 Weeks in Patients With Active Crohn's Disease
Query!
Secondary ID [1]
0
0
91494
Query!
Secondary ID [2]
0
0
310187
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Crohn Disease
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Crohn's disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Sargramostim (Leukine)
Treatment: Drugs - Placebo
Experimental: Arm 1 -
Placebo Comparator: Arm 2 -
Treatment: Drugs: Sargramostim (Leukine)
Sargramostim 6 mcg/kg subcutaneously once daily
Treatment: Drugs: Placebo
Placebo subcutaneously once daily
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
To induce clinical remission and/or clinical response following 8 weeks of treatment
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
8 weeks
Query!
Secondary outcome [1]
0
0
To assess the safety profile of sargramostim (including development of antibodies against sargramostim)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
During study treatment
Query!
Secondary outcome [2]
0
0
To assess quality of life (QoL)
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
During study treatment
Query!
Eligibility
Key inclusion criteria
1. Written informed consent
2. Male or female, age >/= 18 years
3. Confirmed diagnosis of Crohn's disease (endoscopic or radiological evaluation) at
least 4 months prior to receiving the first dose of study drug
4. Moderately to severely active Crohn's disease at time of screening (i.e., CDAI greater
than or equal to 220 and less than or equal to 475 points)
5. If under treatment for Crohn's disease, medication must be stable for at least 4 weeks
prior to receiving the first dose of study drug. The following therapies are allowed:
- Oral therapy with salicylates (mesalamine, sulfasalazine, olsalazine, or
balsalazide) for Crohn's disease
- Antibiotics or probiotics for Crohn's disease
- Topical rectal therapy with mesalamine
6. Females of child-bearing potential:
Negative pregnancy test within 72 hours prior to receiving the first dose of study
drug
7. Sexually-active males and females of child-bearing potential:
Agreement to use adequate method of contraception throughout the study
8. Ability to self-inject study drug or availability of a designee who can do so
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Pregnancy or breast-feeding
2. Colostomy or ileostomy
3. Immediate need for gastrointestinal (GI) surgery for active GI bleeding, peritonitis,
intestinal obstruction, or intra-abdominal or perianal abscess requiring surgical
drainage
4. GI surgery within 6 months prior to receiving the first dose of study drug
5. Symptoms of bowel obstruction or confirmed evidence of a clinically-significant
stricture within the last 6 months that has not been surgically corrected
6. Positive stool test results for any of the following:
Bacteria:
- Salmonella spec.
- Shigella spec.
- Campylobacter spec.
Bacterial toxin:
- Clostridium difficile
Ova and parasites:
- Amoeba spec.
- Giardia spec.
- Cryptosporidium spec.
7. Any of the following laboratory abnormalities:
- Serum creatinine >/= 2.0 mg/dL
- Alkaline phosphatase (AP), aspartate aminotransferase (AST), alanine
aminotransferase (ALT), or total bilirubin >/=; 2 x the upper limit of normal
- Hemoglobin (Hgb) < 8.0 g/dL
- Absolute neutrophil count (ANC) </= 1,000 cells/µL or > cells 20,000/µL
8. Planned in-patient hospitalization during the study
9. Presence or history of cancer of any type (except treated basal cell carcinoma) or
definite dysplasia of the colon within the last 5 years
10. Use of any of the following medications during the specified period of time prior to
receiving the first dose of study drug:
At any time:
- Recombinant human GM CSF (sargramostim or molgramostim)
- Granulocyte colony-stimulating factor (G CSF; filgrastim or pegfilgrastim)
- Natalizumab 8 weeks: or 5 half-lives (whichever is longer)
- Licensed/registered and/or experimental anti-tumor necrosis factor (TNF) therapy
such as infliximab or adalimumab 4 weeks:
- 6-mercaptopurine
- Azathioprine
- Cyclophosphamide
- Methotrexate
- Mycophenolate mofetil
- Tacrolimus
- Cyclosporine
- Thalidomide
- Glucocorticoids, including budesonide and prednisone, or local glucocorticoid
therapy for Crohn's disease
- Any other immunosuppressive drugs
11. Use of any investigational drug within 4 weeks or 5 half-lives (whichever is longer)
prior to receiving the first dose of study drug
12. Use of nutritional therapy (parenteral nutrition or enteral nutrition with elemental
or semi-elemental diets) within 4 weeks prior to receiving the first dose of study
drug. If the physician judges that nutritional supplementation is needed, enteral
nutritional supplements will be allowed for patients who have been receiving a stable
regimen for at least 4 weeks prior to receiving the first dose of study drug and that
is intended to continue through the 8 week treatment period.
13. History of allergy to yeast products or to sargramostim or to any other excipient of
the study drug formulation
14. Active drug or alcohol abuse
15. Clinically important co-morbid conditions unrelated to Crohn's disease as determined
by the investigator
16. Previous randomization into this study, or into any other study of the sponsor's
sargramostim development program
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2006
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/10/2006
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
33
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
- Liverpool
Query!
Recruitment hospital [2]
0
0
- Caboolture
Query!
Recruitment hospital [3]
0
0
- Adelaide
Query!
Recruitment hospital [4]
0
0
- Frankston
Query!
Recruitment hospital [5]
0
0
- Melbourne
Query!
Recruitment hospital [6]
0
0
- Brisbane
Query!
Recruitment hospital [7]
0
0
- Hamilton
Query!
Recruitment hospital [8]
0
0
- Sydney
Query!
Recruitment postcode(s) [1]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [2]
0
0
- Caboolture
Query!
Recruitment postcode(s) [3]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [4]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [5]
0
0
3084 - Melbourne
Query!
Recruitment postcode(s) [6]
0
0
QLD 4000 - Brisbane
Query!
Recruitment postcode(s) [7]
0
0
3204 - Hamilton
Query!
Recruitment postcode(s) [8]
0
0
- Sydney
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
District of Columbia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maryland
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Minnesota
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Nebraska
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New Jersey
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New York
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
North Carolina
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Ohio
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Oklahoma
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Pennsylvania
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
South Carolina
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Texas
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Virginia
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Washington
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
Santa Catarina
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
SP
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
Santos
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Sao Paulo
Query!
Country [28]
0
0
Bulgaria
Query!
State/province [28]
0
0
Sofia
Query!
Country [29]
0
0
Bulgaria
Query!
State/province [29]
0
0
Varna
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
British Columbia
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
Manitoba
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
New Brunswick
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Newfoundland and Labrador
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Ontario
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Quebec
Query!
Country [36]
0
0
Israel
Query!
State/province [36]
0
0
Haifa
Query!
Country [37]
0
0
Israel
Query!
State/province [37]
0
0
Jerusalem
Query!
Country [38]
0
0
Israel
Query!
State/province [38]
0
0
Rehovot
Query!
Country [39]
0
0
Israel
Query!
State/province [39]
0
0
Tel Aviv
Query!
Country [40]
0
0
Israel
Query!
State/province [40]
0
0
Zerifin
Query!
Country [41]
0
0
New Zealand
Query!
State/province [41]
0
0
Auckland
Query!
Country [42]
0
0
New Zealand
Query!
State/province [42]
0
0
Dunedin
Query!
Country [43]
0
0
New Zealand
Query!
State/province [43]
0
0
Hamilton
Query!
Country [44]
0
0
New Zealand
Query!
State/province [44]
0
0
Tauranga
Query!
Country [45]
0
0
Romania
Query!
State/province [45]
0
0
Bucharest
Query!
Country [46]
0
0
Romania
Query!
State/province [46]
0
0
Craiova
Query!
Country [47]
0
0
Russian Federation
Query!
State/province [47]
0
0
Kazan
Query!
Country [48]
0
0
Russian Federation
Query!
State/province [48]
0
0
Krasnodar
Query!
Country [49]
0
0
Russian Federation
Query!
State/province [49]
0
0
Moskva
Query!
Country [50]
0
0
Russian Federation
Query!
State/province [50]
0
0
Sankt-Peterburg
Query!
Country [51]
0
0
Russian Federation
Query!
State/province [51]
0
0
St. Petersburg
Query!
Country [52]
0
0
South Africa
Query!
State/province [52]
0
0
Eastern Cape
Query!
Country [53]
0
0
South Africa
Query!
State/province [53]
0
0
Gauteng
Query!
Country [54]
0
0
South Africa
Query!
State/province [54]
0
0
Western Cape
Query!
Country [55]
0
0
South Africa
Query!
State/province [55]
0
0
Durban
Query!
Country [56]
0
0
Ukraine
Query!
State/province [56]
0
0
Dnepropetrovsk
Query!
Country [57]
0
0
Ukraine
Query!
State/province [57]
0
0
Ivano-Frankovsk
Query!
Country [58]
0
0
Ukraine
Query!
State/province [58]
0
0
Kharkiv
Query!
Country [59]
0
0
Ukraine
Query!
State/province [59]
0
0
Kiev
Query!
Country [60]
0
0
Ukraine
Query!
State/province [60]
0
0
Lviv
Query!
Country [61]
0
0
Ukraine
Query!
State/province [61]
0
0
Zaporozhye
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Genzyme, a Sanofi Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate if Leukine can induce clinical response or remission
in patients with Crohn's disease.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00295165
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Monitor
Query!
Address
0
0
Genzyme, a Sanofi Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00295165
Download to PDF